SYNAIRGEN PLC LS-,01

Synairgen shareholders at a general meeting approved a special resolution for voluntary liquidation; 965,052,834 votes were cast in favour and 510,853 against. Mark Smith and Jonathan Bass of Menzies LLP were appointed joint liquidators of Synairgen and its subsidiary Synairgen Research. The liquidators are granted the powers under the Insolvency Act 1986 to realise and distribute the company’s assets and will be remunerated on a time-cost basis. Accounting records will be kept by the company secretary for twelve months after dissolution; financial and trading records will be retained for at least six years. » Plus sur de.investing.com

Synairgen has convened a general meeting for 8 September 2026 at which shareholders will vote on initiating a Members’ Voluntary Liquidation. The board has stated that both the company and its subsidiary Synairgen Research Limited remain solvent; the sole asset is the inhaled interferon‑beta treatment SNG001. A circular with background information, the proposed resolution and voting instructions will be sent to shareholders by post and email; the announcement follows a prior notice on 31 July 2026 regarding an orderly wind‑down. » Plus sur de.investing.com

Synairgen announces completion of winding-down activities, identifies SNG001 as its sole asset, discontinues non-clinical R&D, closes sites and settles personnel and financial matters. A liquidation circular with a proposed resolution and notice of general meeting is due to be sent by the end of August 2026; the general meeting is planned for September 2026. After shareholder approval the voluntary liquidation will be initiated, a first interim payment is expected in October 2026 and a final distribution in H1 2027; the company anticipates total distributions of more than £5 million, subject to completion costs and advisory fees. » Plus sur de.investing.com

Synairgen has begun preparations for a voluntary liquidation by its shareholders after the early termination of the Phase‑2 INVENT study. The study was stopped because patient recruitment fell far short of expectations; only 11 patients received a dose in the safety cohort, and no safety issues were observed. Synairgen sought buyers or licensees worldwide but did not enter into substantial due‑diligence processes with any party. An insolvency practitioner has been appointed; a timetable for circulars, shareholder resolutions, the start of liquidation and the first distribution is expected in the third quarter. » Plus sur de.investing.com

Synairgen is implementing a cessation of operations and preparing a voluntary liquidation (Members Voluntary Liquidation) after the phase II INVENT study was halted. The company, whose sole asset is the inhaled interferon-beta SNG001, is seeking buyers and has engaged IP advisers and an insolvency practitioner to support the process. Business units, laboratories and subsidiaries are being wound down and more than 100 potential bidders have been approached to maximise proceeds. Synairgen expects to complete the initial steps in the second half of 2026 and to make a first distribution to shareholders. » Plus sur de.investing.com